Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare leukodystrophy caused by mutations in MLC1 or GLIALCAM. The GLIALCAM gene product functions as an MLC1 beta-subunit. We aim to further clarify the molecular mechanisms of MLC caused by mutations in MLC1 or GLIALCAM. For this purpose, we analyzed a human post-mortem brain obtained from an MLC patient, who was homozygous for a missense mutation (S69L) in MLC1. We showed that this mutation affects the stability of MLC1 in vitro and reduces MLC1 protein levels in the brain to almost undetectable. However, the amount of GlialCAM and its localization were nearly unaffected, indicating that MLC1 is not necessary for GlialCAM expression or targeting. These findings were supported by experiments in primary astrocytes and in heterologous cells. In addition, we demonstrated that MLC1 and GlialCAM form homo-and hetero-complexes and that MLC-causing mutations in GLIALCAM mainly reduce the formation of GlialCAM homo-complexes, leading to a defect in the trafficking of GlialCAM alone to cell junctions. GLIALCAM mutations also affect the trafficking of its associated molecule MLC1, explaining why GLIALCAM and MLC1 mutations lead to the same disease: MLC.
INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, OMIM 604004) is a rare type of leukodystrophy (1) , characterized by macrocephaly which appears during the first year of life. After several years, slow neurological deterioration with cerebellar ataxia and spasticity occurs. MRI reveals diffuse signal abnormality and swelling of the cerebral white matter and the presence of subcortical cysts, mainly in the anterior temporal regions. Initial studies of a brain biopsy from an MLC patient showed that myelin is vacuolated (2) . The first disease gene, named MLC1, was identified in 2001 (3) . Mutations in MLC1 have been identified in 75% of the MLC patients (4) .
MLC1 is an oligomeric membrane protein that is expressed mainly in the brain and in white blood cells (WBCs) (3, 5) . Within the brain, MLC1 is predominantly located in astrocyte -astrocyte junctions close to blood -and CSF - † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. * To whom correspondence should be addressed at: Faculty of Medicine, Department of Physiological Sciences II, Campus de Bellvitge, Pavelló de Govern, C/Feixa Llarga s/n. 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Tel: +34 934039781; Fax: +34 934024268; Email: restevez@ ub.edu brain barriers, Bergmann glia and main axonal tracts (6 -8) . Knockdown of MLC1 in astrocyte cultures causes vacuolation (9) . In a similar manner, re-examination of the brain biopsy from an MLC patient (2) revealed that vacuoles are also consistently present in astrocytic endfeet (9) . A role of MLC1 in volume regulation of astrocytes has been suggested based on changes in its localization in hypo-osmotic conditions (10) . However, functional data indicating the role of MLC1 are lacking.
Genetic information suggested that at least one other gene is involved in MLC (11, 12) , but genetic linkage studies and studies of candidate genes were negative (13) . Recently, two different phenotypes were described among MLC patients without MLC1 mutations: a classical phenotype which retains the typical clinical and MRI features, as seen in patients with MLC1 mutations, and an improving phenotype which shows transient MLC features and lacks clinical deterioration (14) .
Quantitative proteomic analysis of affinity-purified MLC1 revealed that GlialCAM (15) interacts directly with MLC1. GlialCAM is an Ig-like protein of unknown function (15, 16) . It was shown that GLIALCAM, also called HEPACAM, is the second MLC gene (17) . Interestingly, MLC-causing GLIALCAM mutations are inherited in a recessive manner in patients with the classical phenotype, and in a dominant manner in patients with the improving phenotype (17) .
Missense mutations in MLC1 reduce MLC1 protein expression in vitro (5, 18, 19) and in vivo, as shown in WBCs (19) , although no data are available from brain tissue of MLC patients with missense mutations. Studies in primary astrocytes indicate that most GLIALCAM mutations disrupt the normal localization of MLC1 and GlialCAM in astrocyte -astrocyte junctions (17) , suggesting that their localization is crucial for physiological function.
In the present work, we present a more detailed characterization of the effect of mutations found in MLC1 and GLIAL-CAM. The availability of a brain obtained at autopsy from an MLC patient homozygous for an MLC1 missense mutation greatly facilitated our studies.
RESULTS

Studies on brain samples of an MLC patient
The patient studied was a female who developed a macrocephaly within the first few months of life and after several years experienced a slow motor deterioration, epilepsy and cognitive decline (Fig. 1A) . MRI imaging at the age of 40 years [control (Fig. 1B) versus patient (Fig. 1C) ] showed diffuse signal abnormalities in the cerebral white matter, with global atrophy and presence of subcortical cysts in the anterior temporal region, indicative of MLC. Analysis of the MLC1 gene showed that the patient is homozygous for the mutation c.206C.T. The mutation leads to an amino acid change (S69L) in the predicted first transmembrane domain (Fig. 1D) . DNA of the parents was not available to confirm that they both carry the same mutation. The amino acid change affects a residue that is highly conserved among different species. It has not been observed in 400 control chromosomes and it was detected in other patients with MLC (4), indicating that the mutation is most likely pathogenic. The patient died at the age of 57 years following a Gross examination of the brain revealed reduced cerebral white matter with cavitation in the frontal and parietal lobes (Fig. 1E) . Subcortical U-fibers, internal capsule, corpus callosum, anterior commissure and optic nerves and tracts were better preserved. The cerebellar peduncles and cerebellar white matter appeared normal. Myelin stains confirmed the predominant involvement of the deep cerebral white matter with better preservation of the other white matter structures (Fig. 1F) .
Microscopic examination (Supplementary Material, Fig. S1 ) revealed preservation of the cerebral cortex and alterations limited to the white matter. These alterations consisted of lack of myelin of the deep white matter with cavitation in the most affected areas, reduction in the number of astrocytes and oligodendrocytes and accompanying loss of axons. Many astrocytes in the white matter lacking myelin and in the vicinity of cavities contained aB-crystallin, a stress protein.
Rosenthal fibers were absent. Large numbers of corpora amylacea were found in the damaged white matter. Small and focal perivascular lymphocytes and macrophages were indicative of white matter damage (Supplementary Material, Fig. S1 ). We conclude that the degeneration and the infiltration of immune system cells observed in the MLC brain from the patient are mild.
In vitro studies of the mutation identified in the patient
We introduced the mutation S69L in human MLC1 containing two HA epitope tags, as already described (5) . The first tag at the N-terminus allows detection by western blot and the second tag, which is located in an extracellular loop, allows detection of surface-expressed protein. Localization was assayed in HeLa cells after co-transfection with the GFP-tagged pleckstrin homology (PH) domain of the phospholipase C d1 (PH-GFP), a fluorescent protein probe that specifically labels the plasma membrane. Wild-type MLC1 was mainly detected at the plasma membrane ( Fig. 2A) , co-localizing with Figure 2 . In vitro studies of the defective protein S69L MLC1 with or without GlialCAM. (A and B) HeLa cells were co-transfected with PH-GFP, as a marker of plasma membrane, together with wild-type MLC1 (A) or the S69L-defective protein (B) containing two HA epitope tags. Two days after the transfection, cells were fixed and permeabilized, and immunofluorescence was performed using 3F10 (against the HA epitope tags) as a primary antibody. The bar line corresponds to 20 mm. (C) HeLa cells were transfected with wild-type MLC1 or the S69L-defective protein with HA tags. Plasma membrane levels were measured using a luminescence-based method, as described in Materials and Methods. Data correspond to the average of three experiments, expressed as a percentage of the wildtype MLC1 protein.
* * P , 0.01. The inset shows an overview of the method. (D) Twenty-four hours after transfection, cells were incubated with the protein synthesis inhibitor CHX (100 mg/ml) for the times indicated (0, 1, 3 and 6 h). Cells were harvested, solubilized and processed by western blot against human MLC1. The signal was quantified using the Multigauge software (Fujifilm), and the values were normalized to the value at time 0 for each of the groups (wild-type MLC1, wild-type MLC1+GlialCAM, S69L, S69L+GlialCAM). The result corresponds to the average of three independent experiments. Values depicted are mean + SEM.
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PH-GFP. In contrast, the S69L-MLC1-defective protein was almost exclusively detected in intracellular compartments (Fig. 2B ). Surface expression levels of the defective protein were quantified using a luminescence-based method, which indicated that the defective protein had a reduced surface expression (Fig. 2C) . In other MLC1 proteins containing MLC-causing mutations, it was shown that increased endoplasmatic reticulum-associated degradation (ERAD) and endo-lysosomal-associated degradation (ELAD) contributed to the cell surface expression defect (19) . In these MLC1 pathogenic variants, reduced surface expression was a consequence of reduced stability (19) . We therefore studied the protein stability of this variant in comparison with the wild-type protein, by measuring the remaining protein after incubation with the protein synthesis inhibitor cycloheximide (CHX) (Fig. 2D) . Similarly, a reduced stability was detected for the defective S69L MLC1 protein. We also tested whether the stability of the wild-type and the defective protein S69L-MLC1 was altered by the co-expression of GlialCAM (Fig. 2D) . The results showed that the S69L protein was stabilized by the presence of the GlialCAM molecule, but the defective protein still remained less stable than the wild-type (Fig. 2D ).
Expression studies of MLC1 and GlialCAM in the patient brain With brain tissue from the MLC patient, we validated the in vitro results in native tissue. No apparent MLC1 protein signal was detected by western blot in cell lysates from different brain regions from the patient, whereas MLC1 was clearly detected in a control case (Fig. 3A) . In the control brain, MLC1 immunoreactivity was found in astrocytic processes surrounding blood vessels (Fig. 3B ). In contrast, no MLC1 immunostaining was detected in the brain from the MLC patient (Fig. 3C ).
Similar experiments were performed for GlialCAM (17) . Western blot experiments detected expression in the MLC patient (Fig. 3D) . Quantification of GlialCAM levels in three independent experiments revealed a 40% decrease versus the control brain. However, it cannot be concluded that its expression was changed compared with the control case, as the post-mortem time differs. Immunohistochemistry detected GlialCAM in astrocytic processes surrounding blood vessels, and subventricular and subpial astrocytes in the control case [ Fig. 3E and (17)] and in the brain of the MLC patient.
Expression of GlialCAM in primary astrocytes depleted of MLC1 by RNA interference
We investigated the expression and localization of GlialCAM in primary cultures of astrocytes, which have been depleted of MLC1 by RNA interference (Fig. 4) . Although knockdown of MLC1 was nearly complete, as confirmed by western blot, no changes in endogenous GlialCAM protein expression was found compared with control scrambled-shRNA (SCR)-infected astrocytes (Fig. 4A) . GlialCAM was detected in astrocyte -astrocyte processes in both SCR-transduced ( Fig. 4B ) and MLC1-depleted astrocytes (shRNA 905) (Fig. 4C) . Infection with adenovirus-expressing GlialCAMflag in MLC1-depleted astrocytes also resulted in GlialCAM localization in astrocyte processes (data not shown). Overall, this result, together with the localization studies in the patient, suggests that the GlialCAM subcellular localization is independent of MLC1 expression.
In vitro characterization of GlialCAM -MLC1 interaction
To further increase our understanding of the relationship between MLC1 and GlialCAM, several studies were done expressing both proteins in heterologous systems. Split-TEV (tobacco etch virus protease) interaction assays (20) demonstrated that MLC1 homo-oligomerizes, but also heterooligomerizes, with GlialCAM ( Fig. 5A ). As controls, no interaction was detected with the unrelated proteins 4F2hc [a single transmembrane protein as GlialCAM (21)] and with the adenosine A 2A receptor [A 2A R, a polytopic membrane protein as MLC1 (22)]. In the reverse experiment, GlialCAM homo-oligomerizes, as described earlier (23), and heterooligomerizes with MLC1, but does not interact with the control unrelated proteins 4F2hc and A 2A R (Fig. 5A) (Fig. 5B, right panel) . Thus, both methods (split-TEV and FRET), together with previously reported co-immunoprecipitation experiments (17) , indicate that GlialCAM and MLC1 interact directly, although every method has different sensitivity.
Next, we addressed whether GlialCAM expression modified the surface levels of the MLC1 protein. Using a luminescencebased assay, the levels of MLC1 at the plasma membrane were investigated in transfected cells expressing MLC1 with an extracellular HA epitope, in the presence or absence of Glial-CAM. These studies revealed that expression of GlialCAM did not modify MLC1 surface levels (Fig. 5C ).
Both MLC1 and GlialCAM were reported to be located in tissue in astrocyte -astrocyte junctions (6, 17) . In HeLa cells, MLC1 was detected at the plasma membrane [ Fig. 5D and (5)], but not particularly enriched in cell junctions, as illustrated by the intensity profile of the associated fluorescence (Fig. 5D, inset) . In contrast, GlialCAM expressed alone was clearly detected in most cells in junctions (Fig. 5E, inset) , as reported previously (16, 23) . Interestingly, after co-expression of MLC1 with GlialCAM, both molecules were clearly enriched at cell junctions ( Fig. 5F and G). Quantification of intensity profile calculations revealed that both GlialCAM and MLC1 are enriched at cell junctions in the presence of the other, but GlialCAM does not need MLC1 to be located in cell junctions (Fig. 5) .
GlialCAM-defective proteins showed a reduced tendency to homo-oligomerize
Next, we aimed to analyze the molecular consequences of MLC-causing GLIALCAM mutations in its oligomerization abilities. Using the split-TEV interaction assay, it was shown that all defective proteins except S196Y had a lower tendency to homo-oligomerize than with the wild-type protein (Fig. 6A) .
We subsequently studied whether GlialCAM-defective proteins affected the direct protein -protein interaction with MLC1 (Fig. 6B) . Although the recessive pathogenic variants R92Q and R98C showed a reduction in their ability to heterooligomerize, the proteins containing the recessive mutation S196Y or the dominant mutations R92W and G89D still retained the capacity to oligomerize with MLC1 at similar levels as the wild-type protein.
GlialCAM-defective proteins show a trafficking defect independent of MLC1
As the mutations mainly affect the ability of GlialCAM to homo-oligomerize, then the question was whether the MLC-causing GLIALCAM mutations would affect the localization of GlialCAM per se.
In HeLa cells, wild-type GlialCAM mainly shows two localization patterns: at the plasma membrane ( protein containing the mutation S196Y in HeLa cells (Fig. 7 ) and in astrocytes (Supplementary Material, Fig. S2 ). We investigated whether the localization of MLC1 in junctions when co-expressed in HeLa cells with GlialCAM was altered by the mutations in GLIALCAM. We found that MLC1 was also mislocalized (Fig. 8 ) in all studied GlialCAMdefective proteins, except the S196Y variant.
DISCUSSION
Studies on MLC1 missense mutations indicate that a deficiency of cell-surface MLC1 protein expression is the molecular basis of MLC disease (19) . This hypothesis has been reconfirmed by the present studies on brain tissue from an MLC patient.
Interestingly, the MLC patient studied here was the oldest MLC patient to our knowledge. However, MLC1 protein was undetectable in the brain of the patient. The lack of detailed clinical data for all the MLC patients limits possible correlations between protein expression and the phenotype of each patient. Possible genotype -phenotype correlations are also difficult to estimate due to the high intrafamilial phenotypic variability (24) , the slow progression of the disease and the fact that the disease phenotype may worsen abruptly after trauma or infections. We conclude that, in MLC disease, no correlation can be established between the cellular or clinical phenotype and the genotype. Probably, unknown modifier factors could influence the phenotype.
GlialCAM was identified as a beta-subunit of MLC1 (17) . The present work defines the role of GlialCAM as an escort molecule, necessary to bring MLC1 to cell -cell junctions.
In the MLC patient and in astrocytes depleted of MLC1 by RNA interference, the expression and localization of Glial-CAM are independent of MLC1. GlialCAM molecules may form complex structures involving homo-cis, hetero-cis and trans-interactions with itself and with other molecules (25, 26) . Here, we show that recessive and dominant GLIAL-CAM mutations affect mainly the formation of homooligomeric structures, leading to a trafficking defect. An exception is the S196Y protein variant, for which we have not found any defect. Collectively, the results presented here indicate a direct correlation between the GlialCAM homooligomerization and the subcellular localization of this protein in cellular junctions, suggesting that GlialCAM homooligomerization is a prerequisite for correct targeting. Defective GlialCAM-MLC1 hetero-oligomerization is differentially affected by several GLIALCAM mutations, but it could also contribute to the trafficking defect of MLC1, as MLC1 alone is not able to reach cell -cell junctions.
At present, we do not understand why some mutations behave as recessive and others as dominant. As all dominant mutations identified so far are located in a putative pocket of the immunoglobulin variable domain (17), we could speculate that these mutations may affect trans-interactions between GlialCAM molecules or other unknown proteins, although experimental evidence is lacking.
GlialCAM protein has been also identified as a molecule with a role in cell growth, differentiation, motility and adhesion in various cell types (15, 16, 23, (27) (28) (29) (30) . It could be suggested that these functions of GlialCAM are affected in MLC patients. Whether MLC1 cooperates with GlialCAM in these functions needs to be explored. The biology of the GlialCAM protein could facilitate the understanding of other discoveries that have been obtained about the cell biology of MLC1. For instance, MLC1 was reported to be associated with caveolae (31) , and GlialCAM was shown to be associated with caveolin 1 (32) . Furthermore, localization of MLC1 in astrocytes was found to be dependent on the actin cytoskeleton (9), whereas GlialCAM was also shown to have a direct interaction with actin (28) . Whether the oligomerization state of GlialCAM molecules is necessary for interaction with intracellular complexes which may be important for its localization in cell junctions is an interesting hypothesis that should be tested. In this sense, affinity purification studies revealed co-immunoprecipitation between MLC1 and the junction-associated protein ZO-1 (9) .
In summary, this work offers new interesting clues about the pathogenic mechanism of MLC1 and GLIALCAM mutations. We have shown that the MLC1 protein containing the S69L mutation can be stabilized by the presence of GlialCAM. Probably, GlialCAM increase the stability of the defective protein by protecting from the ERAD or the ELAD mechanisms. These data suggest that a therapeutical strategy aimed Figure 6 . MLC-causing GLIALCAM mutations affect the interaction mainly between GlialCAM molecules. HeLa cells were co-transfected with the indicated constructs, and interaction was monitored by split-TEV assays as described in Materials and Methods. The signal that was obtained for homooligomerization of wild-type GlialCAM (upper panel) or the heterooligomerization of MLC1 and wild-type GlialCAM (lower panel) was set to 100%. Bars indicate the percentage of interaction compared with the interaction between the corresponding wild-type proteins + SEM. The result is the summary of five independent experiments. Bonferroni's multiple comparison test was used.
* P , 0.05; * * P , 0.01; * * * P , 0.001. ns, no significant difference. Statistical significance was probably minor in the heteromeric interaction (MLC1-GlialCAM) compared with the homomeric interaction (GlialCAM-GlialCAM), as the fold signal induction in the split-TEV assays was higher in the homomeric studies.
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Human Molecular Genetics, 2011, Vol. 20, No. 16 at the over-expression of GlialCAM may be beneficial to improve the surface expression of MLC1 protein variants containing MLC-causing mutations, which could be envisaged as new therapies to MLC patients.
MATERIALS AND METHODS
Animal experimentation and human samples
All the experimental protocols have been approved by the Animal Care and Ethics Committee of the University of Barcelona and conformed to the rules set by the Government of Catalunya.
Neuropathological study in a patient's brain sample
The post-mortem delay was 34 h. At autopsy, one hemisphere was cut in coronal sections, 1 cm thick, frozen on dry ice and stored at 2808C until use. The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks. Selected samples were embedded in paraffin. De-waxed sections were stained with hematoxylin and eosin and Klüver-Barrera, or processed for immunohistochemistry. After incubation with methanol and normal serum, the sections were incubated with one of the primary antibodies overnight at 48C. Antibodies to glial fibrillary acidic protein (Dako, Barcelona, Spain), b-amyloid (Boehringer-Ingelheim, Barcelona, Spain) and ubiquitin (Dako) were used at dilutions of 1:250, 1:50 and 1:200, respectively. CD68 (Dako), used as a marker of microglia, was diluted at 1:100. AT8 antibody (Innogenetics, Barcelona, Spain) was used at a dilution of 1:50. Anti-phosphorylated neurofilament antibody RT97 (Boehringer-Ingelheim) was used at a dilution of 1:100. Rabbit polyclonal anti-a-synuclein antibody (Chemicon, Barcelona, Spain) was used at a dilution of 1:3000. TDP-43 was examined using a mouse monoclonal antibody (Abnova, Tebu-Bio, Barcelona, Spain) raised against a full-length recombinant human TARDBP at a dilution of 1:1000. Monoclonal anti-aB-crystallin (Novocastra) was utilized at 1:50 (Stressgen, Bionova, Madrid, Spain). Antibodies to MLC1 (19) and GlialCAM (17) were used, both diluted 1:100. Following incubation with the primary antibody, the sections were incubated with EnVision+ system peroxidase (Dako) for 15 min at room temperature (RT). The peroxidase reaction was visualized with diaminobenzidine and H 2 O 2 .
Control of the immunostaining included omission of the primary antibody; no signal was obtained following incubation with only the secondary antibody. Sections were slightly counterstained with hematoxylin. Human
Genetic analyses of MLC1 mutations
Sequence analysis of MLC1 exons and their surrounding intronic regions was carried out on genomic DNA extracted from blood, as described (4).
Molecular biology
A tetracysteine epitope, compatible with the fluorescein arsenical helix binder (FlAsH) staining method, was introduced at the N-terminus of human MLC1, thus resulting in the following sequence: MAFLNCCPGCCMEPF (tetracysteine epitope is in boldface). This epitope tag did not affect the subcellular localization and the surface expression levels of the tagged protein (data not shown). Plasmids presented herein were made using standard molecular biology techniques employing recombinant PCR and the MultiSite Gateway System (Invitrogen). The integrity of all cloned constructs was confirmed by DNA sequencing.
Cell culture and transfection
HEK-293T or HeLa cells were grown at 378C in an atmosphere of 5% CO 2 in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml streptomycin, 100 mg/ml penicillin and 5% (v/v) fetal bovine serum. The cells were seeded into plates containing or not poly-D-lysine-coated cover slips. Cells were transiently transfected with the corresponding cDNA constructs using Transfectin (Bio-Rad, Hercules, CA, USA) and following the manufacturer's instructions.
Measurement of surface expression in cells by luminescence
Surface expression in transfected mammalian cells was performed as previously described (5) . Briefly, 48 h after transfection, cells were cleaned with PBS and fixed with 3% paraformaldehyde. After PBS washing, cells were then blocked with 1% BSA in PBS for 30 min, and incubated with 1 ml of 3F10 anti-HA antibody at 0.2 mg/ml in blocking solution for 1 h at RT. Cells were washed six times with blocking solution, and incubated for 20 min with 1 ml of a 1:1000 dilution horseradish peroxidase-coupled secondary antibody (donkey anti-rat IgG, Jackson, Suffolk, UK) in blocking solution. Cells were washed four times with blocking solution and eight times with PBS. Luminescence was measured of one dish at a time with 500 ml of Power Signal ELISA solution (Pierce) in a Turner TD-20/20 luminometer (Turner Biosystems, Madison, WI, USA).
Split-TEV method
Split-TEV assay was performed as described (20, 33) but with some modifications. To this end, a mutant form of the TEV protease (S219V) was used, which prevents its self-digestion but does not affect its catalytic efficiency. The oligopeptide substrate used as the TEV protease-recognition site was ENLYFQS, and the chimeric transcription factor used was GV (obtained from the pM3-VP16 vector; Clontech, Nucliber, Madrid, Spain), which contains the yeast Gal4DNA-binding domain and the herpes simplex VP16 transactivation domain. After TEV protease cleavage, GV translocates into the nucleus and induces the reporter Gaussia luciferase gene expression (pNEBr-X1Gluc) (New England BioLabs, IZASA, Barcelona, Spain), which is secreted into the cell culture medium. TEV protease was divided in two fragments: the TEV-N (residues 1 -118) and the TEV-C (residues 119-242). We fused the TEV-N fragment, the TEV protease-recognition site and the chimeric transcription factor GV to the C-terminal of MLC1 and GlialCAM in a pCDNA3 vector containing a CMV promoter. In addition, we fused the TEV-C fragment to the C-terminal of MLC1, GlialCAM wild-type, GlialCAM containing the mutations R92Q, R98C, S196Y, R92W and G89D, and the adenosine 2A receptor (A2AR). The fusion of the TEV-C fragment to 4F2hc was done at the N-terminus. All the proteins with the TEV-C fragments were cloned in a pCDNA6.2/V5-pL Dest, containing the herpes simplex virus thymidine kinase promoter, to provide low-to-moderate levels of expression.
All the expression plasmids were constructed by PCR using a polymerase with proofreading (KOD Hot Start polymerase, Calbiochem, Darnstadt, Germany), adding the attB1, attB2, attB5R or attB5 recombination sites compatible with the MultiSite Gateway System (Invitrogen). All protocols were performed according to the manufacturer's instructions (Invitrogen).
HeLa cells were transiently transfected with the corresponding cDNA constructs. The total DNA transfected was 2 mg, with the following ratios: 0.75 mg of each protein containing the TEV-N and the TEV-C fragments, 0.3 mg of the reporter vector pNEBr-X1GLuc and 0.2 mg of the pCMV-bGal vector, which was used to monitor the transfection efficiency. After 48 h, 20 ml of liquid were removed from the supernatant of the cells and Gaussia luciferase activity was measured in a TD-20/20 luminometer (Turner BioSystems), after the addition of 20 mM native colenterazine. To normalize the data, cells were solubilized and 30 ml of the cell lysates were used to measure the b-galactosidase enzyme activity, using the Luminiscent b-Galactosidase Detection Kit II (Clontech) in the same luminometer.
FlAsH labeling
FlAsH labeling was performed as described (34) . In brief, transfected cells growing on poly-D-lysine-coated cover slips were washed three times with phenol red-free Hank's balanced salt solution (HBSS) with glucose containing (in mM): 137 NaCl, 0.34 Na 2 HPO 4 , 5 KCl, 0.44 KH 2 PO 4 , 0.5 MgCl 2 , 0.4 Mg 2 SO 4 , 1.26 CaCl 2 , 10 HEPES, 2 D-glucose and 1 ascorbic acid (pH 7.4 with NaOH), and then incubated at 378C for 1 h with an HBSS solution containing 500 nM FlAsH/EDT 2 . FlAsH was purchased from Invitrogen and 1,2-ethanedithiol (EDT) from Sigma-Aldrich. Subsequently, to reduce nonspecific labeling, cells were washed once with HBSS containing 250 mM EDT for 10 min at 378C, and thereafter rinsed three times with HBSS to reduce remnants of EDT.
FRET experiments
FRET between CFP and FlAsH in cells expressing the corresponding constructs was determined by donor recovery after acceptor photobleaching, in which FRET is revealed as a significant increase in the fluorescence of the donor (i.e. CFP) after photobleaching of the acceptor (i.e. FlAsH) (35) . FlAsHlabeled cells were mounted in an Attofluor holder and placed on an inverted Axio Observer microscope (Zeiss Microimaging, Oberkochen, Germany) equipped with a 63× oil immersion objective and a dual-emission photometry system (TILL Photonics, Gräfelfing, Germany). A Polychrome V (TILL Photonics) was used as the light source and signals detected by photodiodes were digitized using a Digidata 1440A analog/digital converter (Molecular Devices, Sunnyvale, CA, USA). pCLAMP (Molecular Devices) and GraphPad Prism (GraphPad Prism, San Diego, CA, USA) software were used for data collection and analysis. Therefore, upon excitation at 436 + 10 nm [beam splitter dichroic long-pass (DCLP) 460 nm] and an illumination time set to 10 ms at 10 Hz, the emission light intensities were determined at 535 + 15 nm (FlAsH) and 480 + 20 nm (CFP pre ) with a beam splitter DCLP of 505 nm. No corrections for spillover between channels or direct YFP excitation were made. Subsequently, acceptor photobleaching was performed by direct illumination of FlAsH at 500 nm for 5 min. Finally, the emission intensities of FlAsH and CFP (CFP post ) were recorded again. FRET efficiency was calculated according to the equation: FRET efficiency ¼ 1 2 (CFP pre /CFP post ).
Primary culture and adenoviral transduction
Rat primary astrocyte cultures were prepared as described previously (17) . Construction of adenovirus-expressing wild-type HA-tagged human MLC1 has been described (19) . Adenoviruses expressing human GlialCAM fused to three copies of the flag epitope, either wild-type or containing the recessive mutations R92Q, R98C and S196Y, or the dominant mutations R92W and G89D have been described recently (17) . Transduction of astrocytes was performed as already described (19) .
Immunofluorescence and immunohistochemical studies
Immune sera against N-terminal mouse MLC1 and the N4 anti-N-terminus of human MLC1 antibody were generated and characterized previously (5, 6, 19) . Immune sera against a GlialCAM synthetic peptide have also been described recently (17) .
Tissue immunohistochemistry was performed as previously described (5, 6) . For immunofluorescent staining of cells, these were fixed with PBS containing 3% paraformaldehyde for 15 min, blocked and permeabilized with 10% FBS and 0.1% Triton X-100 in PBS for 2 h at RT. Primary antibodies were diluted in the same solution and incubated overnight at 48C. Cells were washed and incubated for 2 h at RT with secondary antibodies: Alexa-568 goat anti-mouse and Alexa-488 goat anti-rabbit (1:500 dilution; Invitrogen). Cover slips were mounted in Vectashield medium (Vector Laboratories, ATOM, Barcelona, Spain) with 1.5 mg/ml DAPI (Sigma) and visualized using an Olympus DSU spinning disk confocal microscope (Barcelona, Spain). Co-localization and intensity profile experiments were analyzed using ImageJ (http ://rsbweb.nih.gov/ij/). After intensity profile calculations, we defined a ratio (R) considering the signal at the plasma mem- R-value is .1, the signal will be more concentrated at junctions.
Western blot analysis
For western blot studies, lysates were prepared by homogenization of cells in PBS containing 1% Triton X-100 and protease inhibitors: 1 mM pepstatin and leupeptin, 1 mM aprotinin and 1 mM PMSF, incubated for 1 h at 48C and centrifugated. Proteins in supernatants were quantified using the BCA Kit (Pierce, Thermo Scientific, Rockford, IL, USA) and mixed with SDS loading sample buffer. Western blot analysis was performed as described (5) . Membranes were incubated with primary antibodies: anti-MLC1 (1:100), anti-GlialCAM (1:100) and anti-b-actin (1:10 000, Sigma) and secondary antibodies: HRP-conjugated anti-rabbit and anti-mouse (1:10 000; Jackson). Quantification of western blots was performed using Multigauge (Fujifilm, Barcelona, Spain) or ImageJ.
RNA interference
Conditions for knockdown of MLC1 in rat primary astrocytes have been described recently (9) .
